Patents Assigned to Merck Sharp
  • LONG-ACTION IMPLANT FOR TREATMENT OF INFECTIOUS DISEASES
    Publication number: 20200179273
    Abstract: The present invention relates to long-acting implants useful for the treatment of bacterial infections, particularly mycobacterial infections. The invention also relates to methods of use of such long-acting implants for the treatment of mycobacterial infections such as those caused by Mycobacteria tuberculosis.
    Type: Application
    Filed: June 1, 2018
    Publication date: June 11, 2020
    Applicant: Merck Sharp & DohmeCorp
    Inventors: Stephanie Elizabeth Barrett, Seth P. Forster, Marian E. Gindy, Jay A. Grobler, David Brian Olsen, Ryan Stevenson Teller
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE
    Publication number: 20200179291
    Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Santipharp Panmai, Aditya Tatavarti, Andrew M. Farrington, Varsha Biyyala, Leonardo R. Allain, Marcela Nefliu, Gerard R. Klinzing, Jie Ren, Matthew Lamm
  • Cell-Based Reporter Assay for Live Virus Vaccines
    Publication number: 20200181678
    Abstract: The present invention relates to a cell-based reporter assay for determining viral potency comprising A) transfecting cells maintained in media with a promoter-reporter construct and generating reporter enzyme within the cells; B) infecting cells with a live virus or live virus vaccine wherein reporter enzyme is released into media; and C) measuring reporter enzyme intensity in media.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 11, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRIAN K. MEYER, AKHILESH BHAMBHANI, JEFFREY T. BLUE
  • (S)-N-(3-6-ISOPROPOXYPYRIDIN-3-3YL)-1H-INDAZOL-5-YL)-1-(2-(4-4(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H-YL)-2-OXOETHYL)-3(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS
    Publication number: 20200181119
    Abstract: A composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pranav Gupta, Jiansheng Wan
  • Anti-coagulation factor XI antibodies
    Patent number: 10676536
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: June 9, 2020
    Assignees: Merck Sharp & Dohme Corp., ADIMAB, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • Recombinant expression of MOMP antigen
    Patent number: 10675339
    Abstract: The present invention relates to methods for the recombinant expression of Chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes Chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of Chlamydia infection and/or the effects thereof.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 9, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Puneet Khandelwal
  • METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR
    Publication number: 20200171035
    Abstract: The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.
    Type: Application
    Filed: December 6, 2019
    Publication date: June 4, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Matthew J. MARTON, Yair BENITA
  • Synthesis of cephalosporin compounds
    Patent number: 10662202
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising a palladium-catalyzed coupling reaction.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 26, 2020
    Assignee: Merck Sharp & Dohm Corp.
    Inventors: David Waller, Gregory Gazda, Zachary Minden, Lisa Barton, Clifton Leigh
  • Antidiabetic bicyclic compounds
    Patent number: 10662171
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: May 26, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Harry Chobanian, Duane DeMong, Yan Guo, Barbara Pio, Christopher W. Plummer
  • CTLA4 BINDERS
    Publication number: 20200157220
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: November 27, 2019
    Publication date: May 21, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JUHA PUNNONEN, MARIBEL BEAUMONT, MARIE-ANGE BUYSE, CARLO BOUTTON, BRUNO DOMBRECHT, BJORN VICTOR
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200147213
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: May 1, 2018
    Publication date: May 14, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, JR., Yogita Krishnamachari
  • Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 10646494
    Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, Ling Tong, Joseph A. Kozlowski, Craig A. Coburn, De-Yi Yang, Deyou Sha, Jae-Hun Kim, Michael Dwyer, Kartik M Keertikar, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang
  • Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
    Patent number: 10647727
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gregori J. Morriello, Lehua Chang, Ashley Forster, Richard Berger, Kausik K. Nanda, William D. Shipe
  • Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
    Patent number: 10647771
    Abstract: The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jennifer H. Yearley, Linda Liang, Michael Eric Bigler, Christopher John Gibson
  • Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 10647705
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig Gibeau, Brett A. Hopkins, Derun Li, Kun Liu, Meredeth A. McGowan, Nunzio Sciammetta, David Sloman, Catherine White, Hongjun Zhang, Hua Zhou
  • PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
    Publication number: 20200140445
    Abstract: The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: October 31, 2019
    Publication date: May 7, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok ARASAPPAN, Jason M. COX, John S. DEBENHAM, Zhuyan GUO, Jiafang HE, Zahid HUSSAIN, Zhong LAI, Derun LI, Dongfang MENG, Subharekha RAGHAVAN, Sriram TYAGARAJAN
  • 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20200140411
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: October 31, 2019
    Publication date: May 7, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • FILTER HOUSING ASSEMBLY
    Publication number: 20200139284
    Abstract: A filter housing assembly includes a base plate, an adapter block, and a shroud. The base plate may be permanently installed in a fluid-conveying system of conduits. A filter member is secured to a filter-receiving formation such as a pipe nipple extending from the adapter block and the shroud is secured to the adapter block to cover and seal the filter member. The adapter block is releasably secured to the base plate. The arrangement facilitates insertion and removal of the filter housing assembly into and out of the fluid-conveying system of conduits by converting multiple junction points into a single junction point, at which a subassembly consisting of just the shroud and the adapter block are connected into the system.
    Type: Application
    Filed: November 5, 2018
    Publication date: May 7, 2020
    Applicant: Laboratories Merck Sharp & Dohme-Chibret
    Inventors: Bertrand Pessaud, Michael Meyer
  • Mono- and di-PEG IL-10 production; and uses
    Patent number: 10639353
    Abstract: Provided are methods of producing mono- and di-pegylated IL-10.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: May 5, 2020
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
  • Micro-titration vessel
    Patent number: D886942
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 9, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Tinh Nguyen-DeMary